{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:58:00Z","timestamp":1792061880630,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular & Cellular Proteomics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.mcpro.2024.100834","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T06:46:16Z","timestamp":1724913976000},"page":"100834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Identification of a Proteomic Signature for Predicting Immunotherapy Response in Patients With Metastatic Non-Small Cell Lung Cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2741-4073","authenticated-orcid":false,"given":"Patricia","family":"Mondelo-Mac\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-1209","authenticated-orcid":false,"given":"Luis","family":"Le\u00f3n-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Abalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-3079","authenticated-orcid":false,"given":"Susana","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-4961","authenticated-orcid":false,"given":"Mar\u00eda del Pilar","family":"Chantada Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Muinelo-Romay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0114-2292","authenticated-orcid":false,"given":"Roberto","family":"D\u00edaz-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9906-5458","authenticated-orcid":false,"given":"Ana B.","family":"D\u00e1vila-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2024.100834_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mcpro.2024.100834_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.mcpro.2024.100834_bib3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2024.100834_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz293","article-title":"IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC","volume":"30","author":"Spigel","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.mcpro.2024.100834_bib6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2024.100834_bib7","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2024.100834_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2024.100834_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2217\/imt-2017-0187","article-title":"Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity","volume":"10","author":"Rossi","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.mcpro.2024.100834_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A\u00a0review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mcpro.2024.100834_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.678409","article-title":"Hyperprogressive disease in cancers treated with immune checkpoint inhibitors","volume":"12","author":"Shen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mcpro.2024.100834_bib15","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdz196","article-title":"Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?","volume":"30","author":"Hofman","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/oncolo\/oyac047","article-title":"Circulating biomarkers for therapeutic monitoring of anti-cancer agents","volume":"27","author":"Janse van Rensburg","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.mcpro.2024.100834_bib17","article-title":"In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma","volume":"8","author":"Baba\u010di\u0107","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2024.100834_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrg3356","article-title":"Next-generation proteomics: towards an integrative view of proteome dynamics","volume":"14","author":"Altelaar","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.mcpro.2024.100834_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/msb.20178126","article-title":"Data-independent acquisition-based SWATH - MS for quantitative proteomics: a tutorial","volume":"14","author":"Ludwig","year":"2018","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.mcpro.2024.100834_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.talanta.2017.03.091","article-title":"Depleting high-abundant and enriching low-abundant proteins in human serum: an evaluation of sample preparation methods using magnetic nanoparticle, chemical depletion and immunoaffinity techniques","volume":"170","author":"de Jesus","year":"2017","journal-title":"Talanta"},{"key":"10.1016\/j.mcpro.2024.100834_bib21","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/elps.201100183","article-title":"A\u00a0comparison of depletion versus equalization for reducing high-abundance proteins in human serum","volume":"32","author":"Fern\u00e1ndez","year":"2011","journal-title":"Electrophoresis"},{"key":"10.1016\/j.mcpro.2024.100834_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1074\/mcp.M110.003335","article-title":"A\u00a0robust method for quantitative high-throughput analysis of proteomes by 18O labeling","volume":"10","author":"Bonzon-Kulichenko","year":"2011","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.mcpro.2024.100834_bib23","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M112.445304","article-title":"The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes","volume":"288","author":"Perez-Hernandez","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2024.100834_bib24","article-title":"A\u00a0repository of assays to quantify 10,000 human proteins by SWATH-MS","volume":"16","author":"Rosenberger","year":"2014","journal-title":"Sci. Data"},{"key":"10.1016\/j.mcpro.2024.100834_bib25","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mcpro.2024.100834_bib26","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/bioinformatics\/btz898","article-title":"The use of missing values in proteomic data-independent acquisition mass spectrometry to enable disease activity discrimination","volume":"36","author":"McGurk","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.mcpro.2024.100834_bib27","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41598-021-81279-4","article-title":"A\u00a0comparative study of evaluating missing value imputation methods in label-free proteomics","volume":"11","author":"Jin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mcpro.2024.100834_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2024.100834_bib29","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1038\/s41467-021-24112-w","article-title":"Molecular determinants of response to PD-L1 blockade across tumor types","volume":"12","author":"Banchereau","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2024.100834_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mcpro.2024.100834_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib32","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.752005","article-title":"The frequency of DNA mismatch repair deficiency is very low in surgically resected lung carcinoma","volume":"11","author":"Yanagawa","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.747333","article-title":"Application of proteomics in cancer: recent trends and approaches for biomarkers discovery","volume":"8","author":"Kwon","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.mcpro.2024.100834_bib35","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/cancers14041087","article-title":"Circulating proteins associated with response and resistance to neoadjuvant chemotherapy in HER2-positive breast cancer","volume":"14","author":"Chantada-V\u00e1zquez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2024.100834_bib36","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3390\/nano11092384","article-title":"Detection of circulating serum protein biomarkers of non-muscle invasive bladder cancer after protein corona-silver nanoparticles analysis by SWATH-MS","volume":"11","author":"G\u00f3mez","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.mcpro.2024.100834_bib37","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1021\/acs.jproteome.0c00064","article-title":"SWATH-MS analysis of FFPE tissues identifies stathmin as a potential marker of endometrial cancer in patients exposed to tamoxifen","volume":"19","author":"Janacova","year":"2020","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100834_bib38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","article-title":"Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence","volume":"179","author":"Harel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2024.100834_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cell.2018.08.065","article-title":"Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer","volume":"175","author":"Coscia","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2024.100834_bib40","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1021\/acs.jproteome.5b01129","article-title":"Predicting ovarian cancer patients\u2019 clinical response to platinum-based chemotherapy by their tumor proteomic signatures","volume":"15","author":"Yu","year":"2016","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.mcpro.2024.100834_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2022.100435","article-title":"Red blood cells protein profile is modified in breast cancer patients","volume":"21","author":"Pereira-Veiga","year":"2022","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.mcpro.2024.100834_bib42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nature06916","article-title":"Mining the plasma proteome for cancer biomarkers","volume":"452","author":"Hanash","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2024.100834_bib43","article-title":"Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade","volume":"10","author":"Harel","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2024.100834_bib44","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41594-020-00520-2","article-title":"Structure, lipid scrambling activity and role in autophagosome formation of ATG9A","volume":"27","author":"Maeda","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.mcpro.2024.100834_bib45","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.add6967","article-title":"ATG9A prevents TNF cytotoxicity by an unconventional lysosomal targeting pathway","volume":"378","author":"Huyghe","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.mcpro.2024.100834_bib46","article-title":"NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1","volume":"73","author":"Zhiheng","year":"2024","journal-title":"Drug Resist. updates"},{"key":"10.1016\/j.mcpro.2024.100834_bib47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/humu.23031","article-title":"DCDC2 mutations cause neonatal sclerosing cholangitis","volume":"37","author":"Girard","year":"2016","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mcpro.2024.100834_bib48","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/hmg\/ddv009","article-title":"A\u00a0missense mutation in DCDC2 causes human recessive deafness DFNB66, likely by interfering with sensory hair cell and supporting cell cilia length regulation","volume":"24","author":"Grati","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mcpro.2024.100834_bib49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajhg.2014.12.002","article-title":"DCDC2 mutations cause a renal-hepatic ciliopathy by disrupting Wnt signaling","volume":"96","author":"Schueler","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mcpro.2024.100834_bib50","first-page":"3","article-title":"SLCO4A1, as a novel prognostic biomarker of non-small cell lung cancer, promotes cell proliferation and migration","volume":"64","author":"Shihao","year":"2024","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1600-0854.2004.00208.x","article-title":"Cellular, molecular and clinical characterization of patients with hermansky-pudlak syndrome type 5","volume":"5","author":"Huizing","year":"2004","journal-title":"Traffic"},{"key":"10.1016\/j.mcpro.2024.100834_bib52","doi-asserted-by":"crossref","first-page":"7332","DOI":"10.1158\/0008-5472.CAN-08-1087","article-title":"Functional characterization of filamin A interacting protein 1\u2013like, a novel candidate for antivascular cancer therapy","volume":"68","author":"Kwon","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2024.100834_bib53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/gyno.1994.1040","article-title":"Molecular cloning of differentially expressed genes in human epithelial ovarian cancer","volume":"52","author":"Mok","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2024.100834_bib54","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1158\/2767-9764.CRC-22-0233","article-title":"Smoking-associated downregulation of FILIP1L enhances lung adenocarcinoma progression through mucin production, inflammation, and fibrosis","volume":"2","author":"Kw","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.mcpro.2024.100834_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002358","article-title":"A\u00a0novel protein LZTFL1 regulates ciliary trafficking of the BBSome and smoothened","volume":"7","author":"Seo","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.mcpro.2024.100834_bib56","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1158\/0008-5472.CAN-09-3826","article-title":"Tumor-suppressive functions of leucine zipper transcription factor\u2013like 1","volume":"70","author":"Wei","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2024.100834_bib57","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.1073\/pnas.91.25.11963","article-title":"Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A","volume":"91","author":"Farnsworth","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2024.100834_bib58","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.mcpro.2024.100834_bib59","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1074\/mcp.T600050-MCP200","article-title":"The paragon algorithm, a next generation search engine that uses sequence temperature values sequence temperature values and feature probabilities to identify peptides from tandem mass spectra","volume":"6","author":"Shilov","year":"2007","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2024.100834_bib60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jprot.2018.01.003","article-title":"Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection","volume":"175","author":"Ortea","year":"2018","journal-title":"J. Proteomics"},{"key":"10.1016\/j.mcpro.2024.100834_bib62","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.mcpro.2024.100834_bib63","doi-asserted-by":"crossref","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible summary tables with the gtsummary package","volume":"13","author":"Sjoberg Daniel","year":"2021","journal-title":"R J."},{"key":"10.1016\/j.mcpro.2024.100834_bib64","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1471-2164-11-349","article-title":"Comparison of normalization methods for Illumina BeadChip HumanHT-12 v3","volume":"11","author":"Schmid","year":"2010","journal-title":"BMC Genomics"},{"key":"10.1016\/j.mcpro.2024.100834_bib65","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans. Automat. Contr."},{"key":"10.1016\/j.mcpro.2024.100834_bib66","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2024.100834_bib67","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.1073\/pnas.1314810111","article-title":"Visual account of protein investment in cellular functions","volume":"111","author":"Liebermeister","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2024.100834_bib68","series-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.mcpro.2024.100834_bib69","series-title":"Ggplot2: Elegrant Graphics for Data Analysis","author":"Hadley","year":"2016"}],"container-title":["Molecular & Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947624001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947624001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T22:39:59Z","timestamp":1729636799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947624001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1535947624001245"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2024.100834","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of a Proteomic Signature for Predicting Immunotherapy Response in Patients With Metastatic Non-Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2024.100834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100834"}}